Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome

Pediatric Blood and Cancer

Volumn 53, Issue 6, 2009, Pages 1117-1119

  Dragana, Janić Mihailo ^a   Dimitrije, Brašanac Čedomir ^b   Srda, Janković Jovan ^a   Lidija, Dokmanović Bogdan ^a   Nada, Krstovski Radmio ^a   Nada, Kraguljac Kurtović Janko ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Immune cytopenias; Immunology; Pharmacology

Indexed keywords

LACTATE DEHYDROGENASE; PREDNISOLONE; RAPAMYCIN;

ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNITY; CASE REPORT; COOMBS TEST; CORTICOSTEROID THERAPY; FEMALE; HUMAN; INFANT; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; REMISSION; ULTRASOUND;

AUTOIMMUNE DISEASES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LYMPH NODES; LYMPHATIC DISEASES; LYMPHOPROLIFERATIVE DISORDERS; REMISSION INDUCTION; SIROLIMUS;

EID: 71049178335     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22151     Document Type: Article

References (15)

1. Bleesing JJH. Autoimmune lymphoproliferative syndrome. Curr Pharm Des 2005;9:265-278.
2. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: A lesson from the mouse model. J Hum Genet 1998;43:2-8.
3. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997;89: 1341-1348. (Pubitemid 27079998)
4. Poppema S, Maggio E, Van den Berg A. Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma 2004; 45:423-431. (Pubitemid 38196023)
5. Bleesing JJH. Sorting out the causes of ALPS. J Pediatr 2005; 147:571-574.
6. Sleight BJ, Prasad VS, DeLaat C, et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant 1998;22:375-380. (Pubitemid 28401078)
7. Teachey DT, Obzut DA, Axsom K, et al. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome. Blood 2006;108:1965-1971. (Pubitemid 44395007)
8. Kossiva L, Theodoridou M, Mostrou G, et al. Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome. J Pediatr Hematol Oncol 2006; 28:824-826. (Pubitemid 44967678)
9. Heelan BT, Tormey V, Amlot P, et al. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome. Br J Haematol 2002;118:1078-1081. (Pubitemid 35025972)
10. Van der Werff Ten Bosch J, Schotte P, Ferster A, et al. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: Preliminary results of a clinical cohort study and molecular observations. Br J Haematol 2002;117:176-188. (Pubitemid 34304440)
11. Rao VK, Dowdell KC, Dale JK. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/ lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome. Am J Hematol 2007;82:1049-1055.
12. Rao VK, Price S, Perkins K. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 2009;52:847-852.
13. Teachey DT, Greiner R, Seif A, et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol 2009;145:101-106.
14. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci 2003;100:15113-15118. (Pubitemid 37518025)
15. Hui L, Rodrik V, Pielak RM, et al. mTOR-dependent suppression of protein phosphatase 2A is critical for phospholipase D survival signals in human breast cancer cells. J Biol Chem 2005;280: 35829-35835. (Pubitemid 41633850)